title: Serum troponin Ic values in organ donors are related to donor myocardial dysfunction but not to graft dysfunction or rejection in the recipients.
abstract: BACKGROUND
  Increased plasma cardiac troponin I (cTnI) values in heart donors are associated with donor myocardial dysfunction and increased risk of rejection in the recipients. We investigated the association between cTnI values and myocardial dysfunction in potential heart donors and the relationship between donors' cTnI values and recipients' early myocardial function and 1 year survival and risk of rejection.
  
  
  METHODS
  cTnI was measured in 159 consecutive potential heart donors. Myocardial function was estimated by the left ventricular ejection fraction (LVEF) and segmental wall motion abnormalities (SWMA). Results are mean+/-SD (range) or median (interquartile range).
  
  
  RESULTS
  cTnI values in potential donors were 2.1+/-5 ng/ml (0-40.4 ng/ml); cTnI values were significantly (P<0.001) higher: 4.2+/-5.9 ng/ml (0-30.6 ng/ml) for potential donors with LVEF <50% versus LVEF >50%: 1.7+/-4.7 ng/ml (0-40.4 ng/ml). cTnI values were significantly lower for donors without SWMA. cTnI values were significantly (P<0.001) lower for the 90 donors whose hearts were harvested: 1.1+/-2.3 ng/ml (0-15.6 ng/ml) versus the not harvested: 3.6+/-6.9 ng/ml (0-40.4 ng/ml). There were 87 recipients followed for 1 year. Donors' cTnI values were not associated with early alteration of LVEF, incidence of rejection or 1 year recipients' survival.
  
  
  CONCLUSIONS
  Increased cTnI values in potential heart donors are statistically associated with myocardial dysfunction and could be helpful for organ selection. In contrast, cTnI values in heart donors were not associated with graft dysfunction or recipient survival after transplantation.
authors.affiliation: Department of Anesthesia, Centre Hospitalier Universitaire de Nancy, France.
authors.forename: N
authors.initials: N
authors.lastname: Boccheciampe
authors.forename: G
authors.initials: G
authors.lastname: Audibert
authors.forename: O
authors.initials: O
authors.lastname: Rangeard
authors.forename: C
authors.initials: C
authors.lastname: Charpentier
authors.forename: J F
authors.initials: JF
authors.lastname: Perrier
authors.forename: J M
authors.initials: JM
authors.lastname: Lalot
authors.forename: C
authors.initials: C
authors.lastname: Voltz
authors.forename: P
authors.initials: P
authors.lastname: Strub
authors.forename: Carole
authors.initials: C
authors.lastname: Loos-Ayav
authors.forename: C
authors.initials: C
authors.lastname: Meistelman
authors.forename: P M
authors.initials: PM
authors.lastname: Mertes
authors.forename: D
authors.initials: D
authors.lastname: Longrois
mesh_terms: D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000097:blood; D002648:Child; D006084:Graft Rejection / Q000097:blood* / Q000503:physiopathology; D016027:Heart Transplantation; D006801:Humans; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism*; D018579:Patient Selection; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors; D014019:Tissue Donors; D019210:Troponin I / Q000097:blood*
chemical_list: D015415:Biomarkers; D019210:Troponin I